The MaverickDiagnostic System (MDS) uses

silicon chip-based photonic ring resonator

technology to perform multiple simultaneous

rapid tests on a small volume of whole

blood or serum. The system is cloud-connected

for assay protocol retrieval and clinical


Maverick™ Immunoassay Analyzer


  • Benchtop solution available for On-Site or Core Laboratory testing as well as integrated in Merlin
  • Runs four patients simultaneously
  • Runs up to 26 tests on a single drop of blood
  • 250 patients/day
  • High sensitivity and specificity
  • Cloud-connected with CLIA/CAP pathology oversight
  • Dimensions:
    11” high X 16″ wide X 23″ deep

Photonic Ring Resonator Technology


Genalyte has developed multiplex assay detection technology based on silicon photonics that uses ring resonance to measure binding of macromolecules to sensors on a miniature silicon chip. The MaverickDiagnostic System detects changes in resonance wavelength as macromolecules, such as autoantibodies, bind to their respective antigens that are bound to the chip; eliminating the need for fluorescent, luminescent, or radioactive labels used in other immunoassay formats.

SARS-CoV-2 Multi-Antigen Serology Panel

Genalyte’s SARS-CoV-2 antibody test measures reactivity levels for 26 IgG and IgM antibody targets with market leading performance.

Tested by Northshore University, Mayo Clinic, and Scripps, Genalyte’s SARS-CoV-2 antibody test had the highest sensitivity and specificity as compared to central lab machines.

How It Works

Watch Maverick™ Technology In Action

31 Patent Issued and 17 Pending

Our proprietary Maverick™ Diagnostic System (MDS) has 31 patents issued and 17 patents pending worldwide.

Improving Overall Patient Care

In order to improve overall patient care with rapid laboratory diagnostics, Genalyte became a clinical diagnostic provider receiving CLIA certification and CAP accreditation.

FDA Clearance and EUA Authorization

The Maverick™ Diagnostic System (MDS) received FDA clearance for RNP (ribonuceloprotein) assay in October 2019.

In addition, the Maverick™ Diagnostic System (MDS) received Emergency Use Authorization (EUA) by the FDA for SARS-CoV-2 Multi-Antigen Serology Panel in October 2020


Publications • White Papers • Brochures & Posters